SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla hits new all-time highs, fueling community debate around the stock's valuation and future prospects, especially regarding robotaxis. Discussions also cover regulatory issues, with California potentially suspending sales over self-driving claims, though implementation is delayed. Despite mixed news, optimism persists as some anticipate further gains, while others remain cautious due to the stock's high valuation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices reach new all-time highs, fueled by supply concerns and increased industrial demand, particularly for AI data centers. The community is discussing whether this rally is sustainable, with some pointing to historical manipulation and potential pullbacks, while others remain bullish, citing a possible shift in wealth away from crypto and into precious metals. Concerns around a potential China-driven supply squeeze are also circulating.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as anticipation builds around potential cannabis rescheduling following reports of Trump's interest in an executive order. Community discussions are focused on potential catalysts like the removal of 280E tax and uplisting, with many expecting significant gains if rescheduling occurs. The ETF's price action reflects optimism, and some are suggesting potential targets and levels to watch.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending amid discussions of its potential in AI and digital advertising, despite recent volatility. Community members are highlighting news of potential investments in OpenAI and successful satellite launches for its Leo broadband internet constellation. Some traders are noting technical indicators suggesting possible oversold conditions and a potential bullish reversal.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending as retail investors discuss its potential in the robotics sector following its recent merger and Nasdaq debut. Community members are drawing comparisons to previous high-flying stocks, with some setting ambitious price targets. The stock's volatility and potential short squeeze are also prominent discussion points.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending as investors discuss its recent overnight gains and potential short squeeze, while also noting insider selling and low trading volume. The community is analyzing the company's growth potential in the semiconductor sector, particularly its partnerships related to AI and data centers. Some traders are speculating on possible news or a breakout, while others remain cautious due to recent price drops and market conditions.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is surging amid growing anticipation of potential cannabis rescheduling, fueled by news outlets reporting on expected action. Community discussions revolve around potential price targets and short squeezes, with many believing rescheduling would be a game-changer for the industry. As a major player in the cannabis sector, TLRY stands to benefit significantly from any positive regulatory developments.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

DBV Technologies - ADR

DBV Technologies

DBV Technologies ($DBVT) is trending due to positive Phase 3 trial results for its VIASKIN Peanut patch, showing significant desensitization in peanut-allergic children, potentially paving the way for FDA filing. The community is discussing the strong after-hours surge, potential squeeze, and the clinical meaningfulness of the study's desensitization levels. DBVT focuses on immunotherapy via skin patch technology targeting food allergies.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm ($AFRM) is trending after extending its partnership with Amazon for another 5 years, a deal the CFO touts as a win-win. Community members are actively discussing the potential impact of this extended partnership on Affirm's growth, as well as debating the company's valuation and future prospects in the competitive BNPL sector. Some traders point to technical indicators suggesting a bullish outlook, while others remain cautious due to the stock's volatility.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

Shares of Childrens Place are trending, driven by a closed $450M refinancing deal and increased transformation savings estimates, although Q3 results revealed decreased net sales and a net loss. The community is actively discussing the potential for a short squeeze given the high short interest and low float, along with the company's overall turnaround prospects. Some traders believe PLCE is undervalued with catalysts that could propel a significant upward move, while others express concerns about declining financials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven analysts that are covering the stock, Marketbeat.com reports...

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...

Equities Analysts Issue Forecasts for TCRX FY2025 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at HC Wainwright raised their FY2025 EPS estimates for TScan Therapeutics in a research note issued on Thursday, November...

Wedbush Reduces Earnings Estimates for TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Wedbush dropped their FY2025 EPS estimates for TScan Therapeutics in a research note issued to investors on Wednesday...

TScan Therapeutics (NASDAQ:TCRX) Downgraded by Morgan Stanley to "Equal Weight"

Morgan Stanley cut shares of TScan Therapeutics from an "overweight" rating to an "equal weight" rating in a research note on Friday...

HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

HC Wainwright reduced their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday...

TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of...

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the firm, MarketBeat Ratings...

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +60.80% and +50.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Tscan Therapeutics Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.27	--	--	N/A
Q3 '25	-$0.33	-$0.28	16.24%	BEAT
Q2 '25	-$0.33	-$0.28	14.41%	BEAT
Q1 '25	-$0.29	-$0.26	10.86%	BEAT
Q4 '24	-$0.33	-$0.30	9.55%	BEAT

TCRX
Tscan Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest TCRX News

TCRXTscan Therapeutics Inc